An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression

Hiromitsu Hayashi, Takaaki Higashi, Naomi Yokoyama, Takayoshi Kaida, Keita Sakamoto, Yukiko Fukushima, Takatsugu Ishimoto, Hideyuki Kuroki, Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto, Eiji Oki, Toru Beppu, Hideo Baba

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Transcriptional coactivator with PDZ-binding motif (TAZ) and yes-associated protein (YAP) are equivalently placed downstream effectors of the Hippo pathway with oncogenic roles in human cancers. However, the expression profiles of TAZ/YAP differ depending on the cancer cell type, suggesting that these proteins have different roles during cancer progression, yet no studies have examined the biologic significance of the balance between TAZ and YAP expression levels. Here we examined the functional roles of TAZ/YAP in hepatocellular carcinoma progression. We found that TAZ, but not YAP, was predominantly expressed in HCC. TAZ knockdown under normal conditions attenuated cell growth in HCC cells; however, TAZ knockdown combined with 5-fluorouracil treatment significantly increased chemoresistance compared with control cells. Notably, TAZ knockdown induced compensatory YAP expression and was accompanied by upregulation of CD90, a HCC-specific cancer stem cell marker. Continuous treatment with 5-fluorouracil also induced YAP expression and promoted tumor formation in vivo. Conversely, double knockdown of TAZ/YAP reduced chemoresistance and tumorigenicity. Moreover, YAP knockdown aggravated HCC cell growth to a greater degree than TAZ knockdown, and YAP overexpression was strongly associated with poor prognoses in patients with HCC. Collectively, these studies demonstrate that TAZ and YAP exhibit different functional roles in cancer progression, and a shift to predominant YAP expression upon TAZ depletion conferred cancer stem cell-like properties including chemoresistance and tumorigenicity in HCC. Therefore, targeting of both TAZ/YAP will be required for a complete antitumor response in HCC.

Original languageEnglish
Pages (from-to)4985-4997
Number of pages13
JournalCancer Research
Volume75
Issue number22
DOIs
Publication statusPublished - Nov 15 2015

Fingerprint

Neoplastic Stem Cells
Disease Progression
Hepatocellular Carcinoma
Proteins
Neoplasms
Fluorouracil
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. / Hayashi, Hiromitsu; Higashi, Takaaki; Yokoyama, Naomi; Kaida, Takayoshi; Sakamoto, Keita; Fukushima, Yukiko; Ishimoto, Takatsugu; Kuroki, Hideyuki; Nitta, Hidetoshi; Hashimoto, Daisuke; Chikamoto, Akira; Oki, Eiji; Beppu, Toru; Baba, Hideo.

In: Cancer Research, Vol. 75, No. 22, 15.11.2015, p. 4985-4997.

Research output: Contribution to journalArticle

Hayashi, H, Higashi, T, Yokoyama, N, Kaida, T, Sakamoto, K, Fukushima, Y, Ishimoto, T, Kuroki, H, Nitta, H, Hashimoto, D, Chikamoto, A, Oki, E, Beppu, T & Baba, H 2015, 'An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression', Cancer Research, vol. 75, no. 22, pp. 4985-4997. https://doi.org/10.1158/0008-5472.CAN-15-0291
Hayashi, Hiromitsu ; Higashi, Takaaki ; Yokoyama, Naomi ; Kaida, Takayoshi ; Sakamoto, Keita ; Fukushima, Yukiko ; Ishimoto, Takatsugu ; Kuroki, Hideyuki ; Nitta, Hidetoshi ; Hashimoto, Daisuke ; Chikamoto, Akira ; Oki, Eiji ; Beppu, Toru ; Baba, Hideo. / An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. In: Cancer Research. 2015 ; Vol. 75, No. 22. pp. 4985-4997.
@article{ea210f45a3eb4697b39697d5d847c076,
title = "An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression",
abstract = "Transcriptional coactivator with PDZ-binding motif (TAZ) and yes-associated protein (YAP) are equivalently placed downstream effectors of the Hippo pathway with oncogenic roles in human cancers. However, the expression profiles of TAZ/YAP differ depending on the cancer cell type, suggesting that these proteins have different roles during cancer progression, yet no studies have examined the biologic significance of the balance between TAZ and YAP expression levels. Here we examined the functional roles of TAZ/YAP in hepatocellular carcinoma progression. We found that TAZ, but not YAP, was predominantly expressed in HCC. TAZ knockdown under normal conditions attenuated cell growth in HCC cells; however, TAZ knockdown combined with 5-fluorouracil treatment significantly increased chemoresistance compared with control cells. Notably, TAZ knockdown induced compensatory YAP expression and was accompanied by upregulation of CD90, a HCC-specific cancer stem cell marker. Continuous treatment with 5-fluorouracil also induced YAP expression and promoted tumor formation in vivo. Conversely, double knockdown of TAZ/YAP reduced chemoresistance and tumorigenicity. Moreover, YAP knockdown aggravated HCC cell growth to a greater degree than TAZ knockdown, and YAP overexpression was strongly associated with poor prognoses in patients with HCC. Collectively, these studies demonstrate that TAZ and YAP exhibit different functional roles in cancer progression, and a shift to predominant YAP expression upon TAZ depletion conferred cancer stem cell-like properties including chemoresistance and tumorigenicity in HCC. Therefore, targeting of both TAZ/YAP will be required for a complete antitumor response in HCC.",
author = "Hiromitsu Hayashi and Takaaki Higashi and Naomi Yokoyama and Takayoshi Kaida and Keita Sakamoto and Yukiko Fukushima and Takatsugu Ishimoto and Hideyuki Kuroki and Hidetoshi Nitta and Daisuke Hashimoto and Akira Chikamoto and Eiji Oki and Toru Beppu and Hideo Baba",
year = "2015",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0291",
language = "English",
volume = "75",
pages = "4985--4997",
journal = "Cancer Research",
issn = "0008-5472",
number = "22",

}

TY - JOUR

T1 - An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression

AU - Hayashi, Hiromitsu

AU - Higashi, Takaaki

AU - Yokoyama, Naomi

AU - Kaida, Takayoshi

AU - Sakamoto, Keita

AU - Fukushima, Yukiko

AU - Ishimoto, Takatsugu

AU - Kuroki, Hideyuki

AU - Nitta, Hidetoshi

AU - Hashimoto, Daisuke

AU - Chikamoto, Akira

AU - Oki, Eiji

AU - Beppu, Toru

AU - Baba, Hideo

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Transcriptional coactivator with PDZ-binding motif (TAZ) and yes-associated protein (YAP) are equivalently placed downstream effectors of the Hippo pathway with oncogenic roles in human cancers. However, the expression profiles of TAZ/YAP differ depending on the cancer cell type, suggesting that these proteins have different roles during cancer progression, yet no studies have examined the biologic significance of the balance between TAZ and YAP expression levels. Here we examined the functional roles of TAZ/YAP in hepatocellular carcinoma progression. We found that TAZ, but not YAP, was predominantly expressed in HCC. TAZ knockdown under normal conditions attenuated cell growth in HCC cells; however, TAZ knockdown combined with 5-fluorouracil treatment significantly increased chemoresistance compared with control cells. Notably, TAZ knockdown induced compensatory YAP expression and was accompanied by upregulation of CD90, a HCC-specific cancer stem cell marker. Continuous treatment with 5-fluorouracil also induced YAP expression and promoted tumor formation in vivo. Conversely, double knockdown of TAZ/YAP reduced chemoresistance and tumorigenicity. Moreover, YAP knockdown aggravated HCC cell growth to a greater degree than TAZ knockdown, and YAP overexpression was strongly associated with poor prognoses in patients with HCC. Collectively, these studies demonstrate that TAZ and YAP exhibit different functional roles in cancer progression, and a shift to predominant YAP expression upon TAZ depletion conferred cancer stem cell-like properties including chemoresistance and tumorigenicity in HCC. Therefore, targeting of both TAZ/YAP will be required for a complete antitumor response in HCC.

AB - Transcriptional coactivator with PDZ-binding motif (TAZ) and yes-associated protein (YAP) are equivalently placed downstream effectors of the Hippo pathway with oncogenic roles in human cancers. However, the expression profiles of TAZ/YAP differ depending on the cancer cell type, suggesting that these proteins have different roles during cancer progression, yet no studies have examined the biologic significance of the balance between TAZ and YAP expression levels. Here we examined the functional roles of TAZ/YAP in hepatocellular carcinoma progression. We found that TAZ, but not YAP, was predominantly expressed in HCC. TAZ knockdown under normal conditions attenuated cell growth in HCC cells; however, TAZ knockdown combined with 5-fluorouracil treatment significantly increased chemoresistance compared with control cells. Notably, TAZ knockdown induced compensatory YAP expression and was accompanied by upregulation of CD90, a HCC-specific cancer stem cell marker. Continuous treatment with 5-fluorouracil also induced YAP expression and promoted tumor formation in vivo. Conversely, double knockdown of TAZ/YAP reduced chemoresistance and tumorigenicity. Moreover, YAP knockdown aggravated HCC cell growth to a greater degree than TAZ knockdown, and YAP overexpression was strongly associated with poor prognoses in patients with HCC. Collectively, these studies demonstrate that TAZ and YAP exhibit different functional roles in cancer progression, and a shift to predominant YAP expression upon TAZ depletion conferred cancer stem cell-like properties including chemoresistance and tumorigenicity in HCC. Therefore, targeting of both TAZ/YAP will be required for a complete antitumor response in HCC.

UR - http://www.scopus.com/inward/record.url?scp=84955270341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955270341&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0291

DO - 10.1158/0008-5472.CAN-15-0291

M3 - Article

C2 - 26420216

AN - SCOPUS:84955270341

VL - 75

SP - 4985

EP - 4997

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -